Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

Results Show Improvements in RA Signs and Symptoms Compared to Placebo

SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis.

TRU-015 Phase IIb Clinical Trial Protocol and Results

The Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. Patients in the Phase IIb study were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015.

The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period, with a primary endpoint of improvement on the Disease Activity Score (DAS)-28 scale at 12 weeks, and secondary endpoints including response rates at 24 weeks using American College of Rheumatology (ACR) criteria.

Preliminary analysis i
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Calif. , Dec. 22, 2014 Apnea ... expanded corporate offices in Aliso Viejo ... that due to the tremendous growth and worldwide expansion, ... Sales of patented SnoreRx, the anti snore cure have ... He said, "We are now in 23 countries ...
(Date:12/22/2014)... 22, 2014 Cyberonics, Inc. (NASDAQ: CYBX ... and management of epilepsy, today announced it will participate in ... Wednesday, January 14, 2015, in San Francisco ... Chief Executive Officer, will speak at 11:00 AM Pacific Time.  ... by clicking on the Investor Relations link on the Cyberonics ...
(Date:12/22/2014)...  Pfenex Inc. (NYSE MKT: PFNX) today announced the ... filed and is now open and that this program ... Health and Human Services (HHS), through the Biomedical Advanced ... extremely pleased to have the IND now active for ... milestone in our company,s partnership with BARDA as we ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Seven Years Market Exclusivity in PHN Pending Product Approval ... NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... therapies, announced today that the Office of Orphan Product ... (FDA) has granted orphan drug designation for Qutenza(TM) (formerly ...
... , New Insights into the Prediction of IBD Using ... June 2 Prometheus Laboratories Inc., a specialty pharmaceutical ... between an important serologic marker used in the detection ... at risk for celiac disease. In an oral presentation ...
Cached Medicine Technology:NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia 2NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia 3Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 3
(Date:12/22/2014)... Cleveland, OH (PRWEB) December 22, 2014 ... announced three additions to its leadership team: Greg Yarrington ... President of Engineering, and Patrick Wells as Vice President ... plan to add 80 new jobs in 2015 to ... platform, expansion of its platform-as-a-service offerings, and growth of ...
(Date:12/22/2014)... The MedTech industry is gearing up for new ... of PartnerTech AB of Sweden, is prepared to facilitate the ... Certification. , All signs point to growth in the MedTech ... a repeal of the excise tax originally levied to fund ... annual growth of 9.3% and PartnerTech Inc. is prepared to ...
(Date:12/22/2014)... Branch, TX (PRWEB) December 22, 2014 ... revolutionary work glove with many useful features. Customers of ... and can have the new gloves delivered to their ... work gear and hand tools that incorporate heavy duty ... Utility Magnetic Glove allows workers to store metal parts ...
(Date:12/22/2014)... 2014 NAPW honors ... of the Year. She is recognized with this prestigious ... recognized networking organization of professional women in the country, ... of Professional Women is a vibrant networking community with ... Ms. Kreider is passionate and committed to best practices ...
(Date:12/22/2014)... AZ (PRWEB) December 22, 2014 Parker ... the absolute best in Arizona home contracting services reports ... regard to its quality services in 2014. As a ... since the early 1970s, Parker and Sons is a ... reliability. The company works side-by-side with other top quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... is the most common and severe symptom reported by middle-aged ... the menopause, according to a study in the April issue ... the University of Arizona College of Nursing, USA, spoke to ... lighter or heavier and occur at longer or shorter intervals. ...
... TAI,AN, Shandong, China, April 16 /Xinhua-PRNewswire-FirstCall/ --,China RuiTai ... RuiTai, or ,the Company,), a leading producer and ... of China (,PRC,),today announced its financial results for ... Fiscal Year 2007 Highlights -- Sales increased ...
... Executive brings extensive experience in both healthcare and human ... ... 16 Precyse Solutions, the leader in,driving peak performance within Health ... Corporate,Vice President of Human Resources. She joins Precyse from Pegasus,Communications where ...
... Americans,overwhelmingly want their next President to focus ... healthcare, and stemming the,outsourcing of jobs overseas than ... in the U.S., according to the latest "America ... Law Alliance (ELA)., The workplace-issues poll, based ...
... chemicals that protect the brain, study suggests , , ... exercise may help protect against mild cognitive impairment, ... with mild cognitive impairment can handle everyday activities ... events and upcoming appointments. Most, but not all, ...
... percent from baseline ,severe, to moderately painful, improved ... percent and increased patients, mobility almost three-fold, HOBOKEN, ... from osteoarthritis, with half a million Americans having a ... published in the April 2008,edition (Volume 22, issue No ...
Cached Medicine News:Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 2Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 4Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 5Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 6Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 7Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 8Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 9Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 3Health News:Exercise Could Cut Risk of Mild Cognitive Impairment 2Health News:Study Shows Pine Bark Naturally Reduces Osteoarthritis 2Health News:Study Shows Pine Bark Naturally Reduces Osteoarthritis 3Health News:Study Shows Pine Bark Naturally Reduces Osteoarthritis 4Health News:Study Shows Pine Bark Naturally Reduces Osteoarthritis 5
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
... IMMULITE and IMMULITE 1000 assays ... the IMMULITE and IMMULITE 1000, ... which offer simplicity in both ... can be found in a ...
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
... ultimate goal is to provide state-of-the-art rapid ... treatment. Each year millions of people around ... late detection or undetected disease and illness. ... ,By developing, manufacturing and marketing our tests ...
Medicine Products: